• CAS#141758-74-9
  • NameExendin-4
  • For reserach use only and not for human use!

Product Details

MF: C184H282N50O60S

Manufacturers supply cost-effective and customizable Exendin-4 141758-74-9 We supply high quality Exendin-4 (CAS 141758-74-9), in stock, factory directly supply to clients, lower prices, more competitiveness.

What is the Exendin-4 ?

Exendin-4 is , while it's Molecular Formula is C184H282N50O60S. Antidiabetic.

What is the CAS number for Exendin-4 ?

The CAS number of Exendin-4 is 141758-74-9.

More information of Exendin-4 141758-74-9 are:

Synonyms

Exendin3 (Heloderma horridum), 2-glycine-3-L-glutamic acid-;Exendin 4 (Helodermasuspectum) (9CI);Exenatide;AC 2993A;AC 2993LAR;Byetta;DA 3091;EQW;L-Serinamide,L-histidylglycyl-L-a-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-a-aspartyl-L-leucyl-L-seryl-L-lysyl-L-glutaminyl-L-methionyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-alanyl-L-valyl-L-arginyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-a-glutamyl-L-tryptophyl-L-leucyl-L-lysyl-L-asparaginylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-;Exenatide LAR;

CAS Number

141758-74-9

Molecular Formula

C184H282N50O60S

Molecular Weight

4186.57

HS CODE

2933290000

PSA

1775.05000

LogP

-2.16940

What is Exendin-4 (141758-74-9) used for?

Exenatide is the first drug in a new class of anti-diabetics known as the incretin mimetics, and it is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes who are taking metformin, a sulfonylurea, or both, but have not achieved adequate glycemic control. Exenatide is a functional analog of the human incretin Glucagon-Like Peptide-1 (GLP-1). GLP-1 is naturally released from cells in the GI tract in response to food intake and acts on its receptor on b-cells to potentiate glucose-stimulated insulin secretion. Exenatide is a long-acting agonist at the GLP-1 receptor. It is a synthetic version of a 39-amino acid peptide found in the salivary secretions of the Gila monster lizard.also moderates peak serum glucagon levels during hyperglycemic periods following meals, but does not interfere with glucagon release in response to hypoglycemia. The dosing regimen for exenatide is 5 or 10 mg twice daily, administered as a subcutaneous injection within an hour before morning and evening meals. Following subcutaneous administration, peak plasma concentrations of exenatide are reached in 2.1 h, and the plasma pharmacokinetic profile is dose proportional. The most common adverse events reported with exenatide include nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, and dyspepsia.

InChI:InChI=1S/C184H282N50O60S/c1-16-94(10)147(178(289)213-114(52-58-144(257)258)163(274)218-121(73-101-77-195-105-39-24-23-38-103(101)105)168(279)215-116(68-90(2)3)165(276)205-107(41-26-28-61-186)158(269)219-122(75-134(189)243)154(265)198-79-135(244)196-83-139(248)231-63-30-43-129(231)175(286)225-127(87-238)174(285)223-125(85-236)155(266)200-80-136(245)202-96(12)181(292)233-65-32-45-131(233)183(294)234-66-33-46-132(234)182(293)232-64-31-44-130(232)176(287)222-124(84-235)150(190)261)229-170(281)119(71-99-34-19-17-20-35-99)217-166(277)117(69-91(4)5)214-159(270)108(42-29-62-194-184(191)192)212-177(288)146(93(8)9)228-151(262)95(11)203-156(267)111(49-55-141(251)252)208-161(272)112(50-56-142(253)254)209-162(273)113(51-57-143(255)256)210-164(275)115(59-67-295-15)211-160(271)110(47-53-133(188)242)207-157(268)106(40-25-27-60-185)206-172(283)126(86-237)224-167(278)118(70-92(6)7)216-169(280)123(76-145(259)260)220-173(284)128(88-239)226-180(291)149(98(14)241)230-171(282)120(72-100-36-21-18-22-37-100)221-179(290)148(97(13)240)

Articles related to Exendin-4:

How to get the best price on Exendin-4?

Shanghai YaXian Chemical Co., Ltd is a quality supplier and manufacturer of Exendin-4 . You can buy high quality, low price Exendin-4 141758-74-9 here. Contact us.

Inquiry
Product Name:
Company Name:
*Email:

Please enter your email

Tel:
*Content:

Please enter content

*Code:

Please enter content

The fields marked with*are required

Submit